Uganda has partnered with a US-based drug developer – Gilead Sciences, to conduct a five-year clinical trial for injectable and oral drugs for HIV prevention among young women and adolescent girls. FSN’s Michael Baleke, reporting from Kampala, explains that the new drugs are projected to be safer, more cost effective, and improve adherence among recipients.